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Cancer arises as a result of a multi-step process leading from the
initial benign transformation of cells through to overt invasive,
metastatic disease (Lengauer et al, 1998; Raza, 2000; Vogelstein 
et al, 1988). This process takes many years to unfold and the length
of time required strongly suggests that it does so against a back-
ground of rigorous controls aimed at preventing anarchic cell
behaviour which would threaten the life of the individual, human or
animal. It is likely that certain environments, coupled with a genetic
predisposition, alter host cell susceptibility to carcinogenic insults.
The degree of these effects may have a critical bearing on whether
or not an individual exposed to a particular carcinogen develops
malignant disease and, if so, the duration of exposure required for
the tumour to occur. For example the majority of cigarette smokers
never develop lung cancer. In contrast, many individuals do so from
passive smoking only. Cigarette smoking results in chronic airway
inflammation. However, the nature of the local inflammatory envi-
ronment resulting from cigarette smoking is highly variable
depending on polymorphic immune response genes in addition to a
variety of anti-oxidant and DNA repair associated genes (Spitz et
al, 1999). Here it is argued that chronic inflammation, resulting
from infective and/or non-infective agents, may provide the ideal
environment for the development of the cell changes that lead to
cancer. 
THE RELATIONSHIP BETWEEN CHRONIC
IMMUNE ACTIVATION AND MALIGNANCY 
Chronic activation of the immune system is, in itself, associated
with the development of tumours such as lymphomas seen in HIV
induced AIDS or chronic graft versus host disease (GVHD)
(Dalgleish, 1992; Habeshaw et al, 1992). AIDS is also associated
with the development of Kaposi’s sarcoma (KS) a tumour caused,
at least in part, by the herpes virus HHV-8 which in normal
individuals rarely causes aggressive disease (Whitby and Boshoff,
1998). Other long standing infections associated with cancer
include schistosomiasis and bladder cancer (Badawi et al, 1995),
hepatitis B and C virus (HBV and HCV) and liver cancer
(Imperial, 1999), Epstein-Barr virus and a range of lymphoprolif-
erative and solid tumours including Burkitt’s lymphoma
(Kitagawa et al, 2000) and naso-pharyngeal cancer (Liu et al,
2000) and, more recently, Helicobacter pylori and stomach cancer
(Williams and Pounder, 1999). 
However, chronic inflammation, arising as a result of chronic
exposure to a non-infective irritant, may also be associated with
the development of malignant disease (Table 1). Chronic bron-
chitis and emphysema due to cigarette smoking are recognized
risk factors for the development of lung cancer (Mayne et al,
1999). Carcinoma of the oesophago-gastric junction is one of the
fastest rising cancers in the western world and is associated with
chronic oesophagitis, including Barrett’s oesophagus (Jankowski
et al, 1999; McCann, 1999). Mesothelioma arises as a result of
chronic exposure to asbestos fibres. The incidence in exposed indi-
viduals is increasing to such an extent that it is expected that 1 in
100 men in the UK born in the 1940s will die from the disease
(Edwards et al, 2000). The association between chronic inflamma-
tory bowel disease and cancer of the bowel is well established
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majority of colorectal tumours not associated with inflammatory
bowel disease, histology shows that the precursor lesions, whether
adenomas or polyps, are often inflammatory in nature (Higaki
et al, 1999). 
THE INFLAMMATORY ENVIRONMENT
ASSOCIATED WITH THE SUBSEQUENT
DEVELOPMENT OF CANCER 
Whereas the association between chronic immune activation and
the development of cancer has been recognized for some years,
only recently have we begun to understand the mechanisms under-
lying this phenomenon. The first concerns the nature of the local
and systemic immune response seen in patients with chronic
inflammatory conditions known to be associated with the develop-
ment of malignant disease. Immune responses may be broadly
divided into two categories – cell mediated immunity and humoral
immunity. Cell mediated immunity (CMI) is associated with CD4
+ T-lymphocytes which characteristically produce the cytokines
interleukin(IL)-2, interferon-γ and tumour necrosis factor(TNF)-α
(Thl-lymphocytes). Humoral immunity (HI) is associated with
CD4+ T-lymphocytes which characteristically produce IL-4, IL-6
and IL-10 (Th2) (Mosmann and Coffman, 1989). 
Recent experimental evidence suggests that exposure to a foreign
antigen results in upregulation of the non-specific pro-inflammatory
cytokines IL-1α and -β and the Th1 cytokines in inflammatory cells.
Cyclooxygenase (COX)-1 and COX-2 are among the most impor-
tant enzymes involved in the regulation of the immune response and
play a key role in angiogenesis, the inhibition of apoptosis, and cell
proliferation and motility. COX-1 is constitutively expressed by
many cells. In contrast COX-2 is produced in response to exposure
of epithelial, mesenchymal and inflammatory cells to inflammatory
cytokines, (Taketo, 1998; Uotila, 1996; Vane et al, 1998), and infec-
tive and environmental agents known to be associated with the
development of malignant disease such as helicobacter pylori infec-
tion (Sawaoka et al, 1998a), nicotine (Schror et al, 1998) and
tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-
1-butanone (NNK) (El-Bayoumy et al, 1999). Th2 cytokines such as
IL-4 and IL-10, which inhibit the synthesis of Th1 cytokines by
CD4+ T-helper lymphocytes, are produced in COX-2 expressing
environments. These Th2 cytokines not only downregulate both
proinflammatory/Th1 cytokines but also COX-2 expression itself
(Della Bella et al, 1997; Subbaramaiah et al, 1997; Uotila, 1996;
Vane et al, 1998). Chronic antigen exposure may drive a continuous
cycle in which induced pro-inflammatory and Th1 cytokines upreg-
ulate COX-2 leading to chronic Th2 cytokine production and down-
regulation of the pro-inflammatory CMI response. In predisposed
individuals such a cycle may eventually lead to the development of a
predominant HI response environment (Figure 1). 
DOES SUCH AN ENVIRONMENT EXIST IN
CANCER ASSOCIATED CHRONIC
INFLAMMATORY CONDITIONS? 
HIV induced AIDS, associated with the development of
lymphoma and KS (Weiss and Loveday, 1999), and HIV infection
are associated with a reduction in CMI (Westby et al, 1998). 
The enhanced immune activation seen in HIV disease is due to
upregulation of HI responses, which may be important in
474 KJ O’Byrne and AG Dalgleish 
British Journal of Cancer (2001) 85(4), 473–483 © 2001 Cancer Research Campaign
Cyclooxygenase(COX)-2 expression and the 
immune response
Foreign
antigen
Th1 cytokines
+ IL-1α  and -β
COX-2
induces inhibit
Th2 cytokines
Figure 1 Regulation of cyclo-oxygenase expression in the immune
response. IL-1α = interleukin-1α ; IL-1β = interleukin-1β ; COX-2 =
cyclooxygenase-2; Th1 = T-helper cell lymphocyte cytokine pattern 1
associated with cell mediated immune (CMI) responses; Th2 = T-helper 
cell lymphocyte cytokine pattern 2 associated with humoral immune (HI)
responses. Chronic antigen exposure may drive a continuous cycle in which
induced pro-inflammatory and Th1 cytokines upregulate COX-2 leading to
chronic Th2 cytokine production and downregulation of the pro-inflammatory
CMI response. In predisposed individuals such a cycle may eventually lead
to the development of a predominant HI response environment
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Table 1 Factors predisposing to malignancyproviding the necessary environment for EBV and HHV-8 to
induce lymphoma and KS development respectively (Clerici and
Shearer, 1994; Westby et al, 1998). Hence chronic immune activa-
tion associated with a predominant HI response may be a key
factor contributing to the ideal environment necessary for viral
driven tumours to occur. Where evaluated all chronic inflamma-
tory infectious and non-infectious conditions associated with the
development of cancer, including HBV and HCV associated
chronic hepatitis and cirrhosis (Imperial, 1999), HPV associated
cervicitis (al-Saleh et al, 1998; Le Buanec et al, 1999), schistoso-
miasis cystitis (Raziuddin et al, 1991), helicobacter pylori gastritis
(Williams and Pounder, 1999) and asbestos exposure (Bielefeldt-
Ohmann et al, 1996) are associated with similar immune changes
(Table 1). The importance of the antigen induced pro-inflammatory
and Th1 cytokine drive in the development of a Th2 predominant
immune environment and the subsequent development of malig-
nant disease is underlined by the observation that TNF deficient
mice are resistant to skin carcinogenesis (Moore et al, 1999). 
RELATIONSHIP BETWEEN ANGIOGENESIS AND
THE IMMUNE RESPONSE 
The second aspect of chronic immune activation which may predis-
pose to cancer concerns the relationship between the immune
response and angiogenesis. Recent research has indicated that
angiogenesis may play a key role in the development of early
neoplastic lesions and subsequent malignancy (Bergers et al, 1999).
There is considerable evidence that the angiogenesis associated
with normal physiological processes such as wound healing occurs
in the setting of a HI predominant environment (Folkman, 1995;
Kodelja et al, 1997; Schaffer and Barbul, 1998; Singer and Clark,
1999). Co-culture experiments have shown that endothelial cell
proliferation induced by HI stimulated macrophages is 3–3.5 times
higher than that induced by CMI stimulated macrophages (Kodelja
et al, 1997). The importance of Th2 cytokines in the angiogenic
process is underlined by the observation that IL-6 knockout mice
have an impaired capacity to regenerate normal hepatic tissue and
to heal wounds (Gallucci et al, 2000; Wallenius et al, 2000). In
parallel there is suppression of CMI, the latter presumably occur-
ring so that damaged tissues such as skin and muscle do not become
presented to the immune system as non-self and induce an auto-
immune response to healing or healed tissues (Schaffer and Barbul,
1998; Singer and Clark, 1999). In contrast to HI immune response
induced angiogenesis, CMI immune responses tend to inhibit
angiogenesis (Watanabe et al, 1997). The inverse relationship
between CMI suppression and enhanced angiogenesis is seen not
only in wound healing but also in other normal physiological condi-
tions such as ovulation and pregnancy (Bergers et al, 1999;
Folkman, 1995; Piccinni et al, 1998; Richards et al, 1995). 
Unlike normal physiological processes, the factors that suppress
CM1 and switch on angiogenesis persist in many established
chronic infection/inflammatory states, particularly those condi-
tions discussed earlier that are associated with the development of
malignant disease (Table 1). If this state occurs for several years
then random mutations in the cells of the affected tissues, caused
by carcinogens or unregulated proliferation, would occur in an
immunologically tolerant environment. Phenotypic changes, e.g.
proteins resulting from mutations in the ras oncogene, which
would normally be detected by cytotoxic lymphocytes, may escape
immune surveillance thus allowing another step in the stochastic
progression towards malignancy to occur (Gjertsen 
et al, 1997). Indeed, it is so important for this environment to be
maintained that developing neoplastic cell clones evolve to mimic
this state in order to progress and metastasize. 
Again induction of COX-2 may be central to the development of
an angiogenic environment in many of the conditions leading to the
subsequent development of malignancy. COX-2 expressing tumour
cells are associated with the production of a number of angiogenic
growth factors and the synthesis and activation of matrix metallo-
proteinases favouring tumour invasion and angiogenesis (Tsujii 
et al, 1997; Tsujii et al, 1998; Takahashi et al, 1999). 
THE IMMUNE RESPONSE AND ANGIOGENESIS
IN MALIGNANT DISEASE 
Where studied, all malignancies are associated with suppression of
CMI (Lee et al, 1997; Maraveyas et al, 1999; Pettit et al, 2000).
Indeed, even early stage Dukes A colorectal patients have a
suppressed CMI response which reverts to normal upon surgical
removal of the tumour (Heriot et al, 2000). The dramatic nature of
this response suggests that the HI predominant, pro-angiogenic envi-
ronment is an absolute requirement for further disease progression. If
a tumour requires shielding from immune surveillance to grow, then
it will employ such tactics in order to metastasize and seed into other
tissue sites. The number of documented strategies employed by
cancers to evade the immune response continues to expand. These
include the downregulation of HLA and costimulatory molecules,
production of immunosuppressive factors and upregulation of
immune cell apoptosis inducing molecules such as Fas L (Doherty 
et al, 1994; Ganss and Hanahan, 1998; Garrido et al, 1993; Gorter
and Meri, 1999; Melief and Kast, 1991; Strand and Galle, 1998;
Pettit et al, 2000). In keeping with the avoidance of immune surveil-
lance, COX-2 is constitutively upregulated in a range of premalig-
nant lesions and tumours including those arising from the colon and
rectum, stomach, lung, pancreas, head and neck and breast (Murata
et al, 1999; Koshiba et al, 1999; Mestre et al, 1999; Molina et al,
1999; Wolff et al, 1998; Huang et al, 1998; Taketo, 1998; Tsujii et al,
1997; Uotila, 1996; Vainio and Morgan, 1998; Vane et al, 1998). 
Angiogenesis, the formation of new blood vessels from an
existing vasculature, is essential for tumour growth beyond 1–2m m
in diameter. This process occurs in all tumours and is under the regu-
lation of pro-angiogenic factors including Th2 cytokines such as IL-
6 and vascular endothelial growth factor (VEGF). The intensity
of the angiogenic process, as assessed by microvessel counting
methods, correlates with primary tumour growth, invasiveness, and
metastatic spread of disease (Folkman, 1995; O’Byrne et al, 2000) 
If the immune surveillance evading mechanisms and the angio-
genesis observed in malignant disease processes are indeed central
to tumour growth and metastasis it would appear logical to suppose
that the environment within which malignant transformation occurs
might have similar characteristics. This contention is supported by
the observation that all of the chronic immune activated disease
processes studied to date which predispose to the development of
malignant disease are associated with a suppressed CMI and an
upregulated HI, proangiogenic environment as discussed (Table 1). 
CHRONIC INFLAMMATION AND INHIBITION OF
APOPTOSIS 
In both non-neoplastic and neoplastic cells COX-2 is associated
with cell proliferation (Tsuji et al, 1996) (McGinty et al, 2000) and
inhibition of apoptosis at least in part through the induction of 
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bcl-2 (Tsujii and DuBois, 1995). There is increasing evidence that
exposure to carcinogens such as ultraviolet B light (Athar et al,
2001), the tobacco specific carcinogen 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK) (El-Bayoumy et al, 1999) and nico-
tine (Saareks et al, 1998), and helicobacter pylori (Konturek 
et al, 2000; Sawaoka et al, 1998a) leads to the upregulation of
COX-2 in the affected tissue 
Carcinogens act, at least in part, through the induction of growth
factors and activation of growth factor receptors. An example of a
growth factor known to be induced by carcinogenic insults is the
epidermal growth factor receptor (EGFR) which is upregulated in
many malignant and pre-malignant conditions including those of
the lung (Cox et al, 2000). In the keratinocyte ultraviolet (UV)-B
irradiation have been demonstrated to induce EGFR phosphoryla-
tion and activation of the extracellular-regulated kinase 1 and 2
(ERK1/2) pathways. This occurs secondary to oxidative stress,
itself caused by UV-B generated H2O2. Pretreatment of the cells
with the specific EGFR inhibitor PD153035 followed by UVB
induced H2O2 production reduces the clonogenic potential of
keratinocytes. This reduced proliferation is associated with
increased apoptosis and cell death (Peus et al, 2000). Likewise,
asbestos fibres result in upregulation and phosphorylation of
EGFR in mesothelial cells and, after 48 h, selection of cells which
survive the initial apoptotic effects of the fibres and proliferate
(Faux et al, 2000). These results indicate that EGFR phosphoryla-
tion induces downstream signaling pathways which play a funda-
mental role in regulating cell survival mechanisms following
oxidative stress (Peus et al, 2000). Given these results it is there-
fore not surprising that recent data indicate that EGFR activation
results in COX-2 expression (Mestre et al, 1999). 
The pathways involved in EGFR upregulation of COX-2 and
cell survival remain to be fully elucidated but current evidence
suggests an important role for nuclear factor (NF)-kβ , a transcription
factor important in the regulation of a number of genes intrinsic to
inflammation and cell proliferation (Thanos and Maniatis, 1995).
EGFR phosphorylation activates phosphatidylinositol 3-kinase
(PI3K) (Hu et al, 1992). Activation of PI3K generates phospho-
tidylinositol-3, 4-P2 which in turn recruits and activates the down-
stream serine/threonine kinase, Akt. Activated Akt phosphorylates
specific targets such as Bad (del Peso et al, 1997) and procaspase-
9 (Cardone et al, 1998) with the result of promoting cell survival.
PI3K is involved in the activation of the transcription factor NF-kβ
(Beraud et al, 1999). Activation of NF-kβ via the Akt signalling
pathway is involved in cell survival and resistance to apoptosis
induced by TNF-a (Zhou et al, 2000). Carcinogenic asbestos fibres
induce NF-kβ activation in Simian Virus (SV)-40 transformed
mesothelial (MET 5A) cells and this is linked to cell proliferation
(Faux and Howden, 1997; Janssen et al, 1997; Faux et al, 2000).
Using gel mobility shift assays pretreatment with the selective
EGFR tyrosine kinase inhibitor, PKI166 (Novartis
Pharmaceuticals), has been demonstrated to inhibit the DNA
binding of NF-kβ . Both PKI166 and NF-kβ decoy proteins reduce
cell viability demonstrating the importance of this pathway in cell
proliferation and survival (Faux et al, 2001). The NF-kβ binding
motif is found in the promoter region of the COX-2 gene (Du Bois
et al, 1998). In keeping with the important role of pro-inflamma-
tory cytokines and angiogenic growth factors in the carcinogenic
process IL-1β and bFGF combined with EGF have been shown to
enhance the induction of COX-2 (Majima et al, 1997; Yucel-
Lindberg et al, 1999). 
Macrophage inhibitory factor (MIF) is released during inflam-
matory states and has recently been shown to repress the transcrip-
tion activity of p53 and its downstream targets of p21 and bax,
thereby having a marked anti-apoptotic effect (Cordon-Cardo and
Prives, 1999; Hudson et al, 1999). Hence, inflammation can
actively contribute to the perturbation of probably the single most
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Figure 2 Sequence of events which occurs in those chronic inflammatory conditions known to predispose to the development of cancer. cAMP = cyclic
Adenosine monophosphate; PI3K = phosphatidylinositol-3-kinase; IL-1β = interleukin-1β ; TNF-α = tumour necrosis factor-α ; NF-kβ = nuclear factor-kβ ; COX-2 =
cyclo-oxygenase-2; TGF-β = transforming growth factor-β ; VEGF = vascular endothelial growth factor; IGF-I = insulin-like growth factor-I; MIP = macrophage
inhibitory factor; PGE2 = prostaglandin-E2. Exposure to a carcinogen known to induce chronic inflammation/immune activation may lead to changes both in the
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important cell regulatory pathway in cancer control, thus further
preventing the body’s own cellular defences from reacting to a
mutagenic or stochastic event. P53 also plays a central role in the
regulation of angiogenesis, in part through induction of the anti-
angiogenic factor thrombospondin (Dameron, 1994), and the
mediation of Th1 cytokine induced cytotoxicity (Kano et al, 1997;
Yeung and Lau, 1998). As such, loss of p53 would also facilitate
angiogenesis and be associated with an impaired CMI response. A
number of other cytokines, including TNF and GM-CSF, and
growth factors such as insulin-like growth factor (IGF)-I have also
been implicated directly in cell cycle and angiogenic control,
which, under the appropriate circumstances, could lead to
enhanced carcinogenesis (O’Byrne et al, 2000). 
Therefore, as well as inducing angiogenesis and a HI predomi-
nant immune response, chronic inflammation may also lead to
inhibition of apoptosis in the affected cells. The reactive oxygen
species induced by carcinogens and the formation of carcinogenic
metabolites produced by the inflammatory process, e.g. malondi-
aldehyde resulting from the metabolism of arachidonic acid by
COX-2 (Subbaramiah et al, 1997), may lead directly to DNA
damage and subsequent mutations. Under these circumstances,
and through microenvironmental selection pressures (Pettit et al,
2000), mutated cell populations may not only survive but
thrive, transform and eventually take on a malignant phenotype
(Figure 2). 
ONCOGENIC VIRUSES AND CANCER 
Whilst it is clear that viral infections such as HBV and HCV do not
cause cancer unless chronic inflammation occurs, and then only
after many years have passed, the situation is often less clear-cut
for other oncogenic viruses. For example human papilloma virus
(HPV) is clearly linked to the development of cancer of the cervix.
Elegant molecular mechanisms have demonstrated that the E6 and
E7 human papilloma virus proteins bind to and inhibit the activity
of the P53 and retinoblastoma (rb) tumour suppressor gene
proteins (Dalgleish, 1991). However, only in the past few years is
evidence accumulating that persistent HPV infection is associated
with a chronically immune activated state locally in the cervix and,
perhaps also systemically. While over 25% of females are infected
at ages 19–25, less than 5% remain infected over 35 years of age.
It is possible that these observations may be explained by differ-
ences in the methodology for detecting the virus and by sampling
error. Nonetheless, recent studies indicate that failure to clear the
viral infection results in persistent inflammation with chronic
cervicitis and an increased risk of developing cancer of the cervix
(Cerqueira et al, 1998; White et al, 1992; Hsieh et al, 1999). This
may be contributed to by co-infection with chlamydia. HPV and
chlamydial infection have been shown to be associated with
increased proliferation of the ectocervical epithelium. This is asso-
ciated with reduced apoptosis (Vaganova, 2000). HPV is associ-
ated with increased circulating levels of IL-2 soluble receptor, a
non-specific marker of inflammation, in a proportion of otherwise
normal infected individuals. The number of infected individuals
with elevated levels rises significantly with the development of
CIN and subsequently invasive cervical cancer (Hildesheim et al,
1997; Ung et al, 1999). A recent longitudinal study of HPV
infected patients, in which the virus was detected using the hybrid
capture II assay, demonstrated that a proportion of patients
found to have persistent infection after 2–3 assessments developed
cervical intraepithelial neoplasia (CIN). In contrast those
individuals found to have cleared the infection did not develop any
CIN lesions (Clavel et al, 2000). Several studies have indicated
that clearance of the virus is associated with the development of a
CMI response including IL-2 Th1 responses to the c-terminal
domain of the HPV-16 E2 protein (Bonktes et al, 1999), upregula-
tion of IFN-γ in exfoliated cervical cells (Scott et al, 1999) and an
IgA antibody response (Bonktes et al, 1999). Indeed, the presence
of a hypersensitivity reaction, an indicator of a CMI response, to
the HPV-16 oncoprotein E7 is associated with the subsequent
regression of CIN lesions (Hopfl et al, 2000). In contrast in
patients with active CIN, Th2 immune responses predominate with
an increased IL-10/IL-12 ratio in whole blood supernatants
(Jacobs et al, 1998). CD3+ DR+ antigen peripheral blood 
T-lymphocytes, and the level of CD4+ T-cells have been shown to
decrease while the level of the CD8+ cells increase in women with
CIN as it progresses to frank carcinoma-in-situ. In contrast the
number of B cells remains unchanged (Spivak et al, 1999). 
Epstein–Barr virus (EBV) is associated with Burkitt’s
Lymphoma (BL) in Africa where it arises in children whose
immune system is chronically activated by malaria (de The
G,1993). Likewise, EBV associated nasopharyngeal cancer (NPC)
occurs in Asia (Liu et al, 2000) where it is prevalent only amongst
people who are exposed to fish treated by a smoke curing process
which may also cause local inflammation (Zheng et al, 1999).
Although the majority of the western population is infected with
EBV only a minority develop associated malignancies, in partic-
ular, lymphomas (Yamamoto et al, 1999; Mauray et al, 2000).
Other malignancies associated with EBV virus infection include
squamous oesophageal (Wang et al, 1999) and gastric cancer
(Takada, 2000). However, there is increasing evidence that even
under these circumstances, in which immune activation may not be
readily apparent, EBV gene products may contribute to the inhibi-
tion of apoptosis, increased angiogenesis, suppression of CMI
responses and a HI predominant environment. EBV transforming
gene product BARF1 (zur Hausen et al, 2000) and EBV BHRF1, a
homologue of the anti-apoptotic factor bcl-2, have been detected in
EBV associated tumours (Liu et al, 2000). BL and natural killer/T-
cell lymphomas growth is supported by EBV-encoded poly(A)(–)
RNA through induction of IL-10 (Kitagawa et al, 2000). In nasal
type extranodal cutaneous natural killer or T(NK/T)-cell
lymphoma recent evidence indicates that expression of the latency
associated EBV genes BHRF1, encoding the bcl-2 homologue,
and BCRF1, encoding viral IL-10 favour tumour growth (Xu et al,
2001). EBV-encoded latent membrane protein 1 (LMP1) activation
of the p38 mitogen-activated protein kinase pathway has been
demonstrated to co-regulate IL-6 and IL-8 (a pro-angiogenic, HI
associated chemokine) production (Eliopoulos et al, 1999, Mauray
et al, 2000). Furthermore a strong association has been found
between LMP1 expression and MMP-9, and metastasis in NPC
(Horikawa et al, 2000). In keeping with the crucial role of pro-
inflammatory cytokines in the pathogenesis of malignant disease
increased IL-1α and IL-1β expression has been observed in
primary NPC and metastases compared to control tissues and this
observation was found to correlate with EBV-encoded viral IL-10
transcript (Huang et al, 1999). 
Simian virus-40 (SV-40) is a virus implicated in the pathogen-
esis of a number of malignancies including mesothelioma, bone
tumours, sarcomas, ependymomas and choroid plexus tumours,
SV-40 virus oncoprotein, SV-40 large T antigen, binds p53 protein
and each of the retinoblastoma family proteins, pRb, p107, and
pRb2/p130 (Carbone et al, 1999; De Luca et al, 1997). Through478 KJ O’Byrne and AG Dalgleish 
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these effects the oncoprotein would facilitate angiogenesis
(Dameron, 1994), reduce Th1 cytokine mediated cytotoxicity
(Kano et al, 1997; Yeung and Lau, 1998) and inhibit apoptosis
(Hudson et al, 1999) thereby predisposing the infected individual
to the development of malignant tumours in infected tissues. 
These data suggest that exposure to human oncogenic viruses
rarely causes cancer unless chronic immune activation or inflam-
mation is also present. Even in those quiescent infectious states
where chronic inflammation may not be readily apparent the local
changes induced by viral oncogenes can result in a HI predomi-
nant, proangiogenic, anti-apoptotic environment conducive to the
development of malignant disease. The same may also be true for
cancers associated with non-infectious carcinogenic insults,
including cigarette smoking and asbestos exposure, which them-
selves cause inflammation. 
CANCER CONTROL AND CHAOS 
Cancer and its environment, including the immune response and
cellular control pathways, represent a complex system of inter-
acting factors. Based on the chaos theory, the factors involved
in the development of cancer represent non-linear or chaotic
processes (Coffey, 1998). Chaos is associated with unpre-
dictability, because too many acting forces are present in the
system, and order, in that such complex processes occur against
the background of major attractors. In the case of the immune
system the simplified concept of CMI and HI immune responses
represent two attractors which in addition to being self-regulatory
with bilateral feedback pathways are affected by certain outside
forces such as chronic infections or chemical and/or physical
irritants (Dalgleish, 1999). 
The major regulatory pathway factors including p53, p21 and
bcl-2, themselves major attractors (or cellular policemen) in their
own right, are also affected. Once significantly perturbated further
stochastic oncogenic effects can progress. The relevance of this
concept is that treatments that return the attractors to normal may
be able to have significant indirect anti-cancer activity if applied
before the cancer has progressed too far. With regards to the
immune response, modulation of Th1/Th2 ratios towards a CMI
predominant phenotype using relevant vaccine/cytokine protocols,
COX-2 inhibitors and other anti-angiogenic agents may be able to
shift the balance away from tumour growth and progression
towards inhibition of tumour cell proliferation and, indeed, tumour
regression. This may be what is occurring in those patients with
solid tumours such as melanoma or renal cell cancer whose
tumours regress following non-specific vaccination with BCG or
similar agents and/or IL-2 therapy (Browning, 1996; Dalgleish,
1999; Vile and Dalgleish, 1996). 
RELEVANCE TO CONTROL AND PREVENTION 
Recent research has clearly demonstrated that non-steroidal anti-
inflammatory drugs (NSAIDs) and specific COX-2 inhibitors can
inhibit solid tumour cell proliferation in vitro and in vivo. These
agents may also prevent haematogenous spread of malignancy
provided the disease over-expresses COX-2, and suppress angio-
genesis and tumour growth in xenografts (Hida et al, 1998; Molina
et al, 1999; Sawaoka et al, 1998b; Sawaoka et al, 1998c; Sawaoka
Figure 3 Chronic immune activation or similar environments may support the development and selection of cells capable of transforming and eventually
assuming a malignant phenotype. With progressive stages the tumour itself becomes the predominant factor downregulating cell mediated immune (CMI) and
upregulating humoral immune (HI) responses and inducing angiogenesis. The situation is further exacerbated by tumour induced hypoxia which likewise inhibits
CMI and induced both a predominant HI immune environment and microvessel formation (O’Byrne et al, 2000) 
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et al, 1999; Tomozawa et al, 1999; Tsuji et al, 1996; Gately, 2000).
Of greater relevance to the contention that chronic immune activa-
tion plays a central role in carcinogenesis is the finding that non-
specific and specific COX-2 inhibitors may inhibit malignant
transformation in a variety of experimental in vivo models
including those for breast and lung cancer (Duperron and
Castonguay, 1997; Lala et al, 1997; Yao et al, 2000). 
There is already considerable evidence in the literature that
long-term exposure to aspirin and other NSAIDs reduces the inci-
dence of oesophageal, gastric, colorectal, bladder and lung cancer
(Castelao et al, 2000; Funkhouser and Sharp, 1995; Giovannucci 
et al, 1995; Giovannucci et al, 1994; Langman et al, 2000;
Paganini-Hill, 1994; Schreinemachers and Everson, 1994; Study,
1992; Thun et al, 1991; Akre et al, 2001). 
Aspirin has a number of effects on cancer cells in vitro such as
enhancing apoptosis. However, it is its effect on the inhibition of
the cyclo oxygenases and, as a result, prostaglandin synthesis and
its subsequent effect on the immune response that is of most
interest because NSAIDs have been shown to prevent tumour
mediated immunosuppression and angiogenesis (Grinwich and
Plescia, 1977; Subbaramaiah et al, 1997; Taketo, 1998; Tsujii et al,
1998; Vane et al, 1998). 
In order to prove that NSAIDs and selective COX-2 inhibitors
have a role in chemoprevention one would want to conduct
randomized studies in thousands of people for several years using
an anti-inflammatory agent versus placebo. 
Not treating cancer one by one 
There is a need to identify individuals at high risk of developing
malignant disease and reduce the ‘promoter’ exposure. In the
absence of obvious factors, such as cigarettes, the reduction 
of inflammation, inhibition of angiogenesis and restoration 
of CMI predominant immune response should be primary goals.
Following the success of tamoxifen and raloxifene in reducing 
the incidence of breast cancer, particularly in at risk patients
(reviewed in Savanthanan and O’Byrne, 2001) this approach
should become a high priority in the chemoprevention of 
tumours at other sites. If successful chemopreventive strategies
may result in a reduction of the number of patients requiring one to
one treatment for established malignant disease at a later time.
Trials could test the relevant contributions of anti-inflammatory,
anti-angiogenic and CMI immune stimulatory agents through their
use as single agents or in combination as chemopreventive and
adjuvant therapies, and in the management of established inoper-
able/metastatic malignant disease. 
EXCEPTIONS THAT PROVE THE RULE? 
Ever since the possible association between chronic infection
and the development of cancer was first recognized, it was felt
that this may be relevant to only a minority of cancers. However,
as previously discussed, many tumours not associated with
chronic infections such as lung, oesophageal and bowel cancers
also fit this model. It therefore behoves us to ask the question
‘what tumours do not appear to be relevant to this model?’.
Ironically the two immunologically associated tumours,
melanoma and renal cell cancer as well as the endocrinologically
sensitive tumours (breast and prostate) do not readily fit and
neither do germ cell tumours and those which are clearly associ-
ated with inherited genetic defects. 
However, in the case of melanoma, not only is there a genetic
susceptibility (fair skinned, freckles, ginger hair, moles) but also a
history of recurrent severe sunburn, a phenomenon associated with
Th1 immune suppression and angiogenesis (Pamphilon et al,
1991). Renal cell cancer may represent a stochastic genetic evolu-
tion on the susceptible gene pool not requiring immune activation
or systemic immunosuppression. However, the majority of renal
cell carcinomas have associated mutations in the Von Hippel
Landau tumour suppressor gene. This is associated with upregula-
tion of the angiogenic growth factor VEGF (Fleming, 1999).
VEGF has recently been recognized to suppress dendritic cell
function, an important mediator of CMI (Gabrilovich et al, 1999).
Interestingly, recent work has also demonstrated that insults to the
kidney, such as dehydration, may be associated with an increase in
cyclo-oxygenase-2 levels which could result in locally suppressed
responses and upregulation of pro-angiogenic growth factors such
as VEGF (Yang et al, 1999). 
The endocrine sensitive tumours, such as breast and prostate
cancer, have been shown to occur more frequently in the presence
of chronic inflammatory histologies (mastitis and prostatitis
respectively) (Monson et al, 1976; Nakata et al, 1993; Prince and
Hildreth, 1986). In a recent study the EBV genome has been
detected in the tumour cells of a significant proportion of patients
with breast cancer but not in surrounding normal breast tissue. The
detection of EBV has also been associated with metastatic spread
of the disease to lymph nodes (Bonnet et al, 1999). As discussed
earlier incorporation of EBV genes into the human genome may
predispose affected tissue to the development of malignant disease
due to inhibition of apoptosis, induction of cell transformation,
enhanced tumour cell invasiveness and the induction of a Th2
predominant, pro-angiogenic environment through the release of
IL-6, IL-8 and IL-10. In the case of prostatitis and prostate cancer
diagnostic confusion is frequent (Jung et al, 1998). PCR detection
of aseptic bacterial infection has been found in chronic prostatitis
(Keay et al, 1999) and acute prostatitis can result in dissemination
of prostate epithelial cells (Dumas et al, 1997). Furthermore,
recent work has clearly demonstrated that the risk of biochemical
relapse following radical prostatectomy is increased in patients
with high grade inflammation surrounding malignant glands (Irani
et al, 1999). It is thus surprising that a possible connection between
prostatitis and prostate cancer has only rarely been commented on
(De Marzo et al, 1999). The endocrine system also interacts
directly with the immune response with Th1 and DHEA steroids
counter-regulating Th2 and cortisol steroid pathways which may
indicate that the inflammatory components may be more subtle
than in non-endocrine tumours (Rook et al, 1994). 
Recent observations indicate an important role for growth
factors in the aetiology of breast and prostate cancer. Prospective
clinical studies have demonstrated that high ‘normal’ IGF-1
levels are associated with the development of these tumours.
IGF-I is an angiogenic growth factor which, in high levels, may
suppress CMI responses (reviewed in O’Byrne et al, 2000).
Recently, IGF-II acting through the IGF-I receptor has been
shown to induce COX-2 and PGE2 expression in colorectal cells
indicating a possible mechanism by which IGF growth factors
may play a key role in the initiation of malignant disease 
(Di Popolo et al, 2000). 
Testicular cancer is increasing rapidly in incidence. The disease
is very sensitive to treatment with cytotoxic chemotherapeutic
agents and the majority of cases treated are cured. It is postulated
that the chemosensitivity is due to the low incidence of p53480 KJ O’Byrne and AG Dalgleish 
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abnormalities detected in the disease. Given that it arises in an
immunologically privileged site the comments regarding p53 and
the interaction with the immune system previously mentioned are
particularly compelling (Guillou et al, 1996). With over 300
different types of cancer there are bound to be alternative patho-
genic pathways. However, if the chronic immune activation hypoth-
esis applies then, at the very least, a significant proportion of all
cancers may be amenable to modulation with combination thera-
pies including anti-inflammatory, anti-angiogenic and CMI/Th1
enhancing agents. The question remains, is there any reason not to
do these studies now? 
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